Gout drug could cut length of hospitalisation in patients with moderate to severe COVID-19
A trial investigating the gout drug colchicine as a treatment for COVID-19 has suggested it reduces the length of both supplemental oxygen therapy and hospitalisation in patients with moderate to severe COVID-19.
Source link
- Underarm Lump After COVID Shot Is Likely Lymph Swelling, Not Breast Cancer, Experts Say - March 2, 2021
- फीस नहीं देने के कारण परीक्षा से नहीं किया जाएगा वंचित: राज्य मंत्री श्री परमार - March 2, 2021
- WHO expert panel strongly advises against use of hydroxychloroquine to prevent COVID-19 - March 2, 2021
- U.S. Flu Vaccinations Hit New Record High This Season - March 2, 2021
- कोरोना वैक्सीनेशन संबंधी जानकारी देने के लिए पांच अधिकारी नामांकित - March 2, 2021
- Why you still can’t visit unmasked, even if you’re fully vaccinated - March 2, 2021
- Vaccinating Oldest First for COVID Saves the Most Lives: Study - March 2, 2021
- पचोर नगर की जलावर्धन योजना के लिए भूमि आवंटित - March 2, 2021
- States easing virus restrictions despite experts’ warnings - March 2, 2021
- Pot May Not Be the Best Rx for a Migraine - March 2, 2021
